{"nctId":"NCT00680914","briefTitle":"Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™","startDateStruct":{"date":"2008-06-10","type":"ACTUAL"},"conditions":["Infections, Streptococcal"],"count":503,"armGroups":[{"label":"Synflorix Group","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumococcal vaccine GSK1024850A (Synflorix)","Biological: GSK Biologicals' Hiberix™"]},{"label":"Prevenar Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Prevenar","Biological: GSK Biologicals' Hiberix™"]}],"interventions":[{"name":"Pneumococcal vaccine GSK1024850A (Synflorix)","otherNames":[]},{"name":"Prevenar","otherNames":[]},{"name":"GSK Biologicals' Hiberix™","otherNames":["Hib"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects between, and including 6-12 weeks of age at the time of the first vaccination.\n* Subjects for whom the investigator believes that their parent(s)/guardian(s) can and will comply with the requirements of the protocol should be enrolled in the study.\n* Written and signed informed consent obtained from the parent(s)/guardian(s) of the child/ward.\n* Free of any known or suspected health problems as established by medical history and clinical examination before entering into the study.\n* Born after a gestation period of 36 to 42 weeks inclusive, with a birth weight of at least 2.5 kilogram.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of the study vaccines, or planned use during the study period.\n* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).\n* Chronic administration of immunosuppressants or other immune-modifying drugs since birth.\n* Planned administration/administration of a vaccine not allowed by the study protocol during the study period. Vaccines included in the Korean routine immunization schedule can be administered at least one week before or at least one month after the administration of the study vaccines. Recommended live vaccines not included in the Korean routine immunization schedule can be given at least one month before or at least one month after the administration of the study vaccines.\n* A family history of congenital or hereditary immunodeficiency.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.\n* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period (Hepatitis B immunoglobulins at birth are allowed).\n* Previous vaccination against Streptococcus pneumoniae and/or Haemophilus influenzae type b.\n* History of, or intercurrent Streptococcus pneumoniae and/or Haemophilus influenzae type b disease.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.\n* History of any neurological disorders or seizures.\n* Major congenital defects or serious chronic illness.\n* Acute disease at the time of enrolment. Study entry should be delayed until the illness has improved.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Vaccine Pneumococcal Serotypes Antibody Concentrations Above the Cut-Off Value","description":"Anti-pneumococcal antibody cut-off value assessed was 0.20 microgram per milliliter (ug/mL).\n\nThe vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"343","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"318","spread":null},{"groupId":"OG001","value":"121","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"343","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"342","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"343","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"340","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"331","spread":null},{"groupId":"OG001","value":"121","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With a Seropositivity Status Against Protein D and Defined Pneumococcal Serotypes","description":"Seropositivity status for protein D is defined as anti protein D (anti-PD) antibody concentrations \\>= 100 Enzyme-Linked Immuno Sorbent Assay (EL) units EL.U/mL.\n\nSeropositivity status for pneumococcal serotypes is defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations \\>= 0.05 ug/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"343","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"337","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"343","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"340","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Serotypes Contained in the Vaccine Above the Cut-off Value","description":"The results were presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. In this assay the cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was \\>= 8.\n\nThe vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value","description":"Anti-pneumococcal antibody cut-off value assessed was 0.20 microgram per milliliter (ug/mL).\n\nPneumococcal cross-reactive serotypes were 6A and 19A.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"232","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"203","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Pneumococal Serotypes Contained in the Vaccine","description":"Concentrations are reported as Geometric Mean Concentrations in ug/mL. Pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.41","spread":null},{"groupId":"OG001","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.00","spread":null},{"groupId":"OG001","value":"5.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.52","spread":null},{"groupId":"OG001","value":"0.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":null},{"groupId":"OG001","value":"2.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.08","spread":null},{"groupId":"OG001","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.39","spread":null},{"groupId":"OG001","value":"5.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.54","spread":null},{"groupId":"OG001","value":"8.51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.80","spread":null},{"groupId":"OG001","value":"5.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.41","spread":null},{"groupId":"OG001","value":"2.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.96","spread":null},{"groupId":"OG001","value":"3.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PD Antibody Concentration","description":"Concentration of anti-PD antibody given as GMC expressed in EL.U/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1622.4","spread":null},{"groupId":"OG001","value":"88.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes","description":"Concentration of cross-reactive pneumococcal serotypes 6A and 19A in ug/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":null},{"groupId":"OG001","value":"0.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":null},{"groupId":"OG001","value":"0.12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes","description":"The results were presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. In this assay the cut-off value for opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A was defined as \\>= 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentrations","description":"Concentration of anti-PRP antibody given as GMC in ug/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.131","spread":null},{"groupId":"OG001","value":"11.844","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Seroprotection Status Against PRP","description":"Seroprotection status is defined as anti-PRP antibody concentrations above 0.15 ug/mL and above 1.0 ug/mL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Local Symptoms","description":"Solicited local symptoms assessed include pain, redness and swelling.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"252","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"182","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Solicited General Symptoms","description":"Solicited general symptoms assessed include drowsiness, fever, irritability and loss of appetite.\n\nFever was defined as axillary temperature \\>= 37.5 degrees Celsius.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"293","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Unsolicited Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAE)","description":"An SAE is any untoward medical occurrence that:\n\nresults in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":56,"n":374},"commonTop":["Irritability","Redness","Pain","Drowsiness","Swelling"]}}}